CINCOR PHARMA, INC.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About CINC
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). It also exploring its utility in ameliorating complications of CKD. It is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.
Find out what a historical investment in CINCOR PHARMA, INC. would be worth today using our CINC stock calculator.
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountCINC FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in CINC
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in CINC
on Stake
Buy CINC from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of CINC from only US$10 with fractional shares
